Codex provides transaction-side clarity for investors, founders, and boards in complex or regulated sectors. From rapid diligence scans to exit readiness and bespoke family office mandates, our advisory combines healthcare and biotech expertise with cross-sector agility. Unlike traditional Big 4 processes, Codex delivers senior-led, narrative-rich support designed for high-stakes boardrooms.
💡 Illustrative examples: Supported a VC in assessing a digital health platform under compressed IC timelines; delivered a governance risk sweep for a family-backed biotech entering Europe.
💡 Illustrative examples: Conducted a dataroom readiness review for a medtech preparing Series C; stress-tested governance documentation for a biotech with cross-border licensing discussions.
Codex partners with internal finance teams or transaction advisors for financial modelling, while focusing on sector diligence, governance, and deal narrative.
💡 Illustrative examples: Prepared a medtech venture for Series C exit discussions; guided a biotech board through investor positioning ahead of a cross-border M&A approach.
💡 Illustrative examples: Advised a family office on cross-border biotech acquisition strategy; developed an ESG-integrated reporting framework for a family-backed healthcare venture.
💡 Illustrative examples: Supported cross-border negotiation strategy for a biotech expansion; designed post-deal integration plan for a digital health platform acquired by a US investor.
🚨 Specialist services. Premium pricing. Limited capacity. Reserved for high-stakes transactions.
Codex Group International — Clarity, structure and momentum for leaders at inflection points.
Stay updated with our latest insights and news.
© 2025 Codex Group International. All rights reserved.